Foundation Medicine Expands Molecular Information Decision Support Offerings With GeneKit

Foundation Medicine announced the expansion of its suite of molecular information-based products with GeneKitTM.

GeneKitTM is a genomics solutions portal for pathologists that is uniquely differentiated by the power of FoundationCORETM.

Stockholders at Foundation Medicine Approve All Pending Roche Transactions
Around 80% of the total outstanding shares of common stock eligible to vote at the meeting were voted in favor of each proposal related to the Roche transaction.

GeneKit is a cloud-based software solution that complements Interactive Cancer Explorer (ICE 2) with PatientMatchTM, which is the company’s innovative physician-facing decision support portal.

GeneKit facilitates the interpretation of genomic data generated by pathologists from targeted next generation sequencing (NGS) and “hot spot” assays.

This integration allows pathologists to more effectively support clinical diagnosis and treatment strategies through the rapid interpretation and efficient reporting of genomic information to oncology care teams.

New Closed-loop Optogenetic Control System Allows Complex Brain Experiments
The new technique will allow for more complicated and nuanced experiments and may set the stage for advanced neurological rehabilitation techniques.

“To ensure that molecular information is used to inform therapeutic decisions and improve patient care, we are offering pathologists a sophisticated clinical interpretation system. GeneKit will allow pathologists to assess a patient’s specific tumor alterations against a knowledgebase of curated genomic variants, relevant scientific research, targeted therapy and clinical trial information, enabling the creation of actionable reports in a timely fashion for care teams,” said David J. Daly, chief commercial officer of Foundation Medicine.

“Today, a large number of institutions use manual interpretation procedures that can be incredibly arduous, technical and time-consuming. GeneKit overcomes these challenges of manual reporting and furnishes pathologists with highly relevant clinical and scientific data for the betterment of patient care,” said David J. Daly.

Protein Mel18 That Turns On Genetic Switch For Cardiac Cell Growth Identified
Harnessing Mel18 also promises to make it easier to grow functioning heart cells in the laboratory from induced pluripotent stem cells or iPS cells.

Source-Medindia

Genetics and Genomics Firm iLife Discoveries Brings Over 50 Genetic Tests to India
The firm currently has 50 tests such as psychogenetic tests, new born screening tests and MammaPrint and Blueprint tests for breast cancer, among others.